This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Standalone September 2026 quarter revenue rises 34% as loss turns to profit
LYKALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.4 pts less than Nifty Microcap 250 and 2.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved unaudited Q2 and half-year results. Standalone Q2 revenue rose 34% to Rs 44.20 crore from Rs 32.97 crore, and profit after tax improved to Rs 1.32 crore from a Rs 3.62 crore loss. Group profit was Rs 1.27 crore versus a Rs 3.21 crore loss. The limited review found no issue. The merger restated prior figures; FY26 included a Rs 33.24 crore exceptional charge. Postal ballot seeks approval to reappoint an independent director.
Revenue growth and a return to profit may support sentiment, but profit margins are thin. Restatements and an exceptional charge reduce comparability.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹44.20 Cr | ₹36.66 Cr | +20.6% |
| Operating profit | ₹0.45 Cr | −₹5.48 Cr | turned positive |
| Profit after tax | ₹1.27 Cr | −₹3.21 Cr | turned positive |
| EBITDA margin | 8.0% | -6.9% | +14.9 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.